Age-related and amyloid-beta-independent tau deposition and its downstream effects

Anika Wuestefeld1, Alexa Pichet Binette1, David Berron1,2

  • 1Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, SE-222 42 Lund, Sweden.

Insights

Age-related tau pathology can occur outside the medial temporal lobe, independent of amyloid-beta. This primary age-related tauopathy affects brain structure and cognition, suggesting new treatment targets.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Gerontology

Background:

  • Amyloid-beta (Aβ) is linked to tau pathology spread, but age-related tau may exist independently.
  • Investigating Aβ-independent tau outside the medial temporal lobe is crucial for understanding brain aging.

Purpose of the Study:

  • To examine age-related tau deposition independent of Aβ outside the medial temporal lobe.
  • To assess the downstream effects of this tau deposition on cognition and brain structure.

Main Methods:

  • Utilized two large cohorts (in vivo PET imaging and ex vivo immunohistochemistry).
  • Measured in vivo tau and Aβ deposition, medial temporal lobe volumes, cortical thickness, and cognitive function.
  • Analyzed ex vivo Aβ load and tau tangle density.

Main Results:

  • Observed age-related tau deposition in medial temporal lobe and cortical regions, independent of Aβ.
  • Tau deposition negatively associated with cortical volume and thickness, independent of Aβ.
  • Age-related cognitive decline was partially mediated by tau in specific brain regions, even with low Aβ.

Conclusions:

  • Provides evidence for primary age-related tauopathy outside the medial temporal lobe.
  • Demonstrates downstream effects of this tauopathy on brain structure and cognition.
  • Suggests potential for tau-targeting treatments in preclinical stages, even with low Aβ pathology.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
549
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
230